Stereotactic Body Radiotherapy (SBRT) With Concurrent Boost for Low- and Intermediate-Risk Prostate Cancer

Inclusion Criteria

• •Histologically proven diagnosis of prostate adenocarcinoma within one year
• •Gleason Score 2-7
• •Clinical T-stage T1b-T2c (AJCC 7th Edition)
• •Clinical Nx or N0, and Mx or M0
• •PSA \< 20 ng/mL
• •Low or intermediate risk according to NCCN guidelines: Low: Clinical Stage (CS) T1b-T2a and Gleason 2-6 and PSA \< 10 ng/ml; Intermediate: CS T2b-T2c and Gleason 2-6 and PSA \< 10 ng/ml, or CS T1b-T2a and Gleason 7 and PSA \< 10 ng/ml, or CS T1b-T2a and Gleason 2-6 and PSA 10-20ng/mL
• •ECOG performance status 0 or 1
• •Has had a pre-treatment PSA drawn within a month of the beginning of protocol therapy
• •If androgen-deprivation therapy (ADT) has been initiated, must have a documented pre-ADT PSA; this baseline PSA should not be obtained during following periods: 1) 10-day period following prostate biopsy; 2) within 30 days after discontinuation of finasteride; or 3) within 90 days after discontinuation of dutasteride.
• •Has completed a baseline health-related quality of life assessment Extended Prostate Cancer Index Composite questionnaire (EPIC-26)
• •Has had a history and physical examination (including digital rectal examination and a formal morbidity assessment via the ACE-27) within 60 days
• •Morbidity score (via the ACE-27) of none (0), mild (1) or moderate (2)
• •Willing and able to use adequate contraception during protocol treatment and for 3 months after the completion of protocol treatment